{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T11:04:51Z","timestamp":1792062291827,"version":"4.4.0"},"reference-count":34,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2024,10,1]]},"abstract":"<jats:sec>\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Olaparib is a poly(adenosine diphosphate\u2013ribose) polymerase inhibitor that provides benefit in combination with hormonal therapies in patients with metastatic prostate cancer who harbor homologous recombination repair (HRR) alterations. Its efficacy in the absence of androgen deprivation therapy has not been tested.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To determine the activity of olaparib monotherapy among patients with high-risk biochemically recurrent (BCR) prostate cancer after radical prostatectomy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>This phase 2, single-arm nonrandomized controlled trial enrolled genetically unselected patients across 4 sites in the US from May 2017 to November 2022. Eligible patients had BCR disease following radical prostatectomy, a prostate-specific antigen (PSA) doubling time of 6 months or shorter, an absolute PSA value of 1.0 ng\/mL or higher, and a testosterone level of 150 ng\/dL or higher.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Intervention<\/jats:title>\n                    <jats:p>Treatment was with olaparib, 300 mg, by mouth twice daily until doubling of the baseline PSA, clinical or radiographic progression, or unacceptable toxic effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main Outcome and Measure<\/jats:title>\n                    <jats:p>The primary end point was a confirmed 50% or higher decline in PSA from baseline (PSA50). Key secondary end points were outcomes by HRR alteration status, as well as safety and tolerability.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of the 51 male patients enrolled (mean [SD] age, 63.8 [6.8] years), 13 participants (26%) had a PSA50 response, all within the HRR-positive group (13 of 27 participants [48%]). All 11 participants with\n                      <jats:italic>BRCA2<\/jats:italic>\n                      alterations experienced a PSA50 response. Common adverse events were fatigue in 32 participants (63%), nausea in 28 (55%), and leukopenia in 22 (43%), and were consistent with known adverse effects of olaparib.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>\n                      In this nonrandomized controlled trial, olaparib monotherapy led to high and durable PSA50 response rates in patients with\n                      <jats:italic>BRCA2<\/jats:italic>\n                      alterations. Olaparib warrants further study as a treatment strategy for some patients with BCR prostate cancer but does not have sufficient activity in those without HRR alterations and should not be considered for those patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>\n                      ClinicalTrials.gov Identifier:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT03047135\">NCT03047135<\/jats:ext-link>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamaoncol.2024.3074","type":"journal-article","created":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T13:56:39Z","timestamp":1724334999000},"page":"1400","source":"Crossref","is-referenced-by-count":20,"title":["Olaparib Without Androgen Deprivation for High-Risk Biochemically Recurrent Prostate Cancer Following Prostatectomy"],"prefix":"10.1001","volume":"10","author":[{"given":"Catherine H.","family":"Marshall","sequence":"first","affiliation":[{"name":"Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin A.","family":"Teply","sequence":"additional","affiliation":[{"name":"University of Nebraska Medical Center, Omaha"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayun","family":"Lu","sequence":"additional","affiliation":[{"name":"Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lia","family":"Oliveira","sequence":"additional","affiliation":[{"name":"Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Wang","sequence":"additional","affiliation":[{"name":"Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shifeng S.","family":"Mao","sequence":"additional","affiliation":[{"name":"Allegheny Health Network Cancer Institute, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Kevin","family":"Kelly","sequence":"additional","affiliation":[{"name":"Thomas Jefferson University Hospital, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Channing J.","family":"Paller","sequence":"additional","affiliation":[{"name":"Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark C.","family":"Markowski","sequence":"additional","affiliation":[{"name":"Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel R.","family":"Denmeade","sequence":"additional","affiliation":[{"name":"Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serina","family":"King","sequence":"additional","affiliation":[{"name":"Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rana","family":"Sullivan","sequence":"additional","affiliation":[{"name":"Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elai","family":"Davicioni","sequence":"additional","affiliation":[{"name":"Veracyte, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Proudfoot","sequence":"additional","affiliation":[{"name":"Veracyte, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario A.","family":"Eisenberger","sequence":"additional","affiliation":[{"name":"Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Carducci","sequence":"additional","affiliation":[{"name":"Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara L.","family":"Lotan","sequence":"additional","affiliation":[{"name":"Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel S.","family":"Antonarakis","sequence":"additional","affiliation":[{"name":"University of Minnesota, Minneapolis"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"24","key":"coi240044r1","doi-asserted-by":"publisher","first-page":"3973","DOI":"10.1200\/JCO.2005.04.0756","article-title":"Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition.","volume":"24","author":"Stephenson","year":"2006","journal-title":"J Clin Oncol"},{"issue":"3","key":"coi240044r2","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1097\/01.ju.0000134888.22332.bb","article-title":"Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results.","volume":"172","author":"Roehl","year":"2004","journal-title":"J Urol"},{"issue":"3","key":"coi240044r3","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1097\/JU.0000000000001797","article-title":"Timing of androgen deprivation treatment for men with biochemical recurrent prostate cancer in the context of novel therapies.","volume":"206","author":"Marshall","year":"2021","journal-title":"J Urol"},{"issue":"6","key":"coi240044r4","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.clgc.2019.08.002","article-title":"PSA doubling time and absolute PSA predict metastasis-free survival in men with biochemically recurrent prostate cancer after radical prostatectomy.","volume":"17","author":"Markowski","year":"2019","journal-title":"Clin Genitourin Cancer"},{"issue":"6","key":"coi240044r5","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/j.eururo.2013.05.025","article-title":"Management of biochemical recurrence after primary treatment of prostate cancer: a systematic review of the literature.","volume":"64","author":"Punnen","year":"2013","journal-title":"Eur Urol"},{"issue":"16","key":"coi240044r6","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1056\/NEJMoa2303974","article-title":"Improved outcomes with enzalutamide in biochemically recurrent prostate cancer.","volume":"389","author":"Freedland","year":"2023","journal-title":"N Engl J Med"},{"issue":"24","key":"coi240044r7","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1056\/NEJMoa2022485","article-title":"Survival with olaparib in metastatic castration-resistant prostate cancer.","volume":"383","author":"Hussain","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"coi240044r8","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1470-2045(19)30684-9","article-title":"Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial.","volume":"21","author":"Mateo","year":"2020","journal-title":"Lancet Oncol"},{"issue":"18","key":"coi240044r9","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","article-title":"DNA-repair defects and olaparib in metastatic prostate cancer.","volume":"373","author":"Mateo","year":"2015","journal-title":"N Engl J Med"},{"issue":"1","key":"coi240044r10","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s41391-018-0086-1","article-title":"Prevalence of DNA repair gene mutations in localized prostate cancer according to clinical and pathologic features: association of Gleason score and tumor stage.","volume":"22","author":"Marshall","year":"2019","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"7573","key":"coi240044r11","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/nature15819","article-title":"Patient-centric trials for therapeutic development in precision oncology.","volume":"526","author":"Biankin","year":"2015","journal-title":"Nature"},{"issue":"11","key":"coi240044r12","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1038\/nbt.2696","article-title":"Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing.","volume":"31","author":"Frampton","year":"2013","journal-title":"Nat Biotechnol"},{"issue":"10106","key":"coi240044r13","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","article-title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.","volume":"390","author":"Coleman","year":"2017","journal-title":"Lancet"},{"issue":"6","key":"coi240044r14","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1200\/JCO.22.01662","article-title":"Phase II randomized study of salvage radiation therapy plus enzalutamide or placebo for high-risk prostate-specific antigen recurrent prostate cancer after radical prostatectomy: the SALV-ENZA trial.","volume":"41","author":"Tran","year":"2023","journal-title":"J Clin Oncol"},{"issue":"18","key":"coi240044r15","doi-asserted-by":"publisher","first-page":"4869","DOI":"10.1158\/1078-0432.CCR-20-0764","article-title":"Genomic and clinicopathologic characterization of ATM-deficient prostate cancer.","volume":"26","author":"Kaur","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"12","key":"coi240044r16","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","article-title":"Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3.","volume":"34","author":"Scher","year":"2016","journal-title":"J Clin Oncol"},{"issue":"6","key":"coi240044r18","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","article-title":"The Molecular Signatures Database (MSigDB) hallmark gene set collection.","volume":"1","author":"Liberzon","year":"2015","journal-title":"Cell Syst"},{"issue":"14","key":"coi240044r19","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1002\/cncr.34790","article-title":"A novel prostate cancer subtyping classifier based on luminal and basal phenotypes.","volume":"129","author":"Weiner","year":"2023","journal-title":"Cancer"},{"issue":"4","key":"coi240044r20","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1038\/s41391-021-00416-2","article-title":"A transcriptomic model for homologous recombination deficiency in prostate cancer.","volume":"25","author":"Weiner","year":"2022","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"9","key":"coi240044r21","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1038\/ng1861","article-title":"A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers.","volume":"38","author":"Carter","year":"2006","journal-title":"Nat Genet"},{"issue":"1","key":"coi240044r22","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ccell.2019.06.005","article-title":"Pan-cancer convergence to a small-cell neuroendocrine phenotype that shares susceptibilities with hematological malignancies.","volume":"36","author":"Balanis","year":"2019","journal-title":"Cancer Cell"},{"issue":"3","key":"coi240044r23","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S1470-2045(10)70295-3","article-title":"Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study.","volume":"12","author":"Cuzick","year":"2011","journal-title":"Lancet Oncol"},{"issue":"14","key":"coi240044r24","doi-asserted-by":"publisher","first-page":"3818","DOI":"10.1158\/1078-0432.CCR-13-3368","article-title":"Prognostic B-cell signatures using mRNA-seq in patients with subtype-specific breast and ovarian cancer.","volume":"20","author":"Iglesia","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"1","key":"coi240044r25","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.celrep.2018.03.075","article-title":"The Cancer Genome Atlas comprehensive molecular characterization of renal cell carcinoma.","volume":"23","author":"Ricketts","year":"2018","journal-title":"Cell Rep"},{"issue":"1","key":"coi240044r26","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.celrep.2016.12.019","article-title":"Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade.","volume":"18","author":"Charoentong","year":"2017","journal-title":"Cell Rep"},{"issue":"4","key":"coi240044r27","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.eururo.2019.02.002","article-title":"Differential response to olaparib treatment among men with metastatic castration-resistant prostate cancer harboring BRCA1 or BRCA2 versus ATM mutations.","volume":"76","author":"Marshall","year":"2019","journal-title":"Eur Urol"},{"issue":"6","key":"coi240044r28","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1200\/JCO.2021.39.6_suppl.100","article-title":"Differential activity of PARP inhibitors in BRCA1- versus BRCA2-altered metastatic castration-resistant prostate cancer (mCRPC).","volume":"39","author":"Taza","year":"2021","journal-title":"J Clin Oncol"},{"issue":"8","key":"coi240044r29","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1056\/NEJMoa2214676","article-title":"Rucaparib or physician\u2019s choice in metastatic prostate cancer.","volume":"388","author":"Fizazi","year":"2023","journal-title":"N Engl J Med"},{"issue":"32","key":"coi240044r30","doi-asserted-by":"publisher","first-page":"3763","DOI":"10.1200\/JCO.20.01035","article-title":"Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 gene alteration.","volume":"38","author":"Abida","year":"2020","journal-title":"J Clin Oncol"},{"issue":"6","key":"coi240044r31","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1200\/JCO.2023.41.6_suppl.18","article-title":"Rucaparib for metastatic castration-resistant prostate cancer (mCRPC): TRITON3 interim overall survival and efficacy of rucaparib vs docetaxel or second-generation androgen pathway inhibitor therapy.","volume":"41","author":"Bryce","year":"2023","journal-title":"J Clin Oncol"},{"issue":"11","key":"coi240044r32","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1158\/1078-0432.CCR-20-0394","article-title":"Non-BRCA DNA damage repair gene alterations and response to the PARP inhibitor rucaparib in metastatic castration-resistant prostate cancer: analysis from the phase II TRITON2 study.","volume":"26","author":"Abida","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"1","key":"coi240044r33","first-page":"14","article-title":"Management of biochemically recurrent prostate cancer after local therapy: evolving standards of care and new directions.","volume":"11","author":"Paller","year":"2013","journal-title":"Clin Adv Hematol Oncol"},{"issue":"1","key":"coi240044r34","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1097\/JU.0000000000001698","article-title":"A phase 2\/3 prospective multicenter study of the diagnostic accuracy of prostate specific membrane antigen PET\/CT with 18F-DCFPyL in prostate cancer patients (OSPREY).","volume":"206","author":"Pienta","year":"2021","journal-title":"J Urol"},{"key":"coi240044r17","doi-asserted-by":"crossref","unstructured":"Parry? MA, Grist? E, Mendes? L, . Clinical testing of transcriptome-wide expression profiles in high-risk localized and metastatic prostate cancer starting androgen deprivation therapy: an ancillary study of the STAMPEDE abiraterone Phase 3 trial.? Res Sq. Published online February 8, 2023. doi:10.21203\/rs.3.rs-2488586\/v1","DOI":"10.21203\/rs.3.rs-2488586\/v1"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2822705\/jamaoncology_marshall_2024_oi_240044_1728488921.51889.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T11:16:16Z","timestamp":1729163776000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2822705"}},"subtitle":["A Nonrandomized Controlled Trial"],"short-title":[],"issued":{"date-parts":[[2024,10,1]]},"references-count":34,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2024.3074","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10,1]]}}}